^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Alecensa (alectinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Immunochemotherapy or Chemotherapy in ALK-rearranged 5'-ALK NSCLC

    Excerpt:
    ...- ALK Arranged Positive...
    Trial ID:
    NCT04997382
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

    Published date:
    12/22/2022
    Excerpt:
    In this study, ALK-positive nonsquamous NSCLC patients previously treated with alectinib received bevacizumab 15 mg/kg on day 1 every 3 weeks and alectinib 600 mg/day until disease progression….Of the 12 patients treated, the median PFS was 3.1 months (95% CI 1.2-16.1), and the median OS was 24.1 months (95% CI 8.3-not estimable).
    DOI:
    10.3390/cancers15010204